LFG
GALT icon

Larson Financial Group’s Galectin Therapeutics GALT Stock Holding History

Larson Financial Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,300
Closed -$1.68K – 3120
2024
Q4 		$1.68K Hold
1,300
– – ﹤0.01% 1922
2024
Q3 		$3.58K Buy
+1,300
New +$3.19K ﹤0.01% 1735

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Larson Financial Group's GALT Position: Q1 2025 in Review

Larson Financial Group sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 1,300 shares — an estimated $1.68K sold.

Larson Financial Group first reported a position in GALT in Q3 2024 and held it in 2 quarters. The position peaked at $3.58K in Q3 2024. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

  • Larson Financial Group reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Larson Financial Group sold 1,300 Galectin Therapeutics shares in Q1 2025, an estimated $1.68K.
  • Larson Financial Group first reported a position in Galectin Therapeutics in Q3 2024 and held it in 2 quarters.
  • Larson Financial Group's Galectin Therapeutics position peaked at $3.58K in Q3 2024.
  • 93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Larson Financial Group's 13F filing for Q1 2025, filed 2 May 2025.